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ABSTRACT
Genetic variations in 3’ untranslated regions of target genes may affect microRNA 
binding, resulting in differential protein expression. microRNAs regulate DNA repair, 
and single-nucleotide polymorphisms in miRNA binding sites (miRSNPs) may account 
for interindividual differences in the DNA repair capacity. Our hypothesis is that 
miRSNPs in relevant DNA repair genes may ultimately affect cancer susceptibility 
and impact prognosis. 
In the present study, we analysed the association of polymorphisms in predicted 
microRNA target sites of double-strand breaks (DSBs) repair genes with colorectal 
cancer (CRC) risk and clinical outcome. Twenty-one miRSNPs in non-homologous 
end-joining and homologous recombination pathways were assessed in 1111 cases 
and 1469 controls. The variant CC genotype of rs2155209 in MRE11A was strongly 
associated with decreased cancer risk when compared with the other genotypes (OR 
0.54, 95% CI 0.38–0.76, p = 0.0004). A reduced expression of the reporter gene was 
observed for the C allele of this polymorphism by in vitro assay, suggesting a more 
efficient interaction with potentially binding miRNAs. In colon cancer patients, the 
rs2155209 CC genotype was associated with shorter survival while the TT genotype of 
RAD52 rs11226 with longer survival when both compared with their respective more 
frequent genotypes (HR 1.63, 95% CI 1.06-2.51, p = 0.03 HR 0.60, 95% CI 0.41–0.89,  
p = 0.01, respectively).
miRSNPs in DSB repair genes involved in the maintenance of genomic stability 
may have a role on CRC susceptibility and clinical outcome.
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INTRODUCTION
Colorectal cancer (CRC) is among the most frequent 
malignancies worldwide and is the third highest cause of 
cancer mortality among men and women [1]. Though 
CRC detected at an early stage can be successfully 
removed, cancers undetected until an advanced stage with 
metastases remain incurable [2]. The growing incidence of 
CRC (2001– 2011 growth index 6.0%) was accompanied 
by a relatively low rate of early detection of the disease 
[3]. Therefore, there is an urgent need to find biomarkers 
to aid prevention, treatment and prognosis in CRC.
The molecular etiology of CRC has been explored 
extensively, revealing that this cancer develops from 
an accumulation of genomic mutations. Accumulating 
cellular DNA damage, if not correctly repaired, can lead 
to genomic instability, apoptosis or senescence and may 
ultimately predispose the organism to various disorders 
including cancers. The importance of DNA repair is 
highlighted by the fact that mutations in a number of 
DNA repair genes lead to human syndromes that include 
multiple cancers, immunodeficiency, and phenotypes with 
chromosomal anomalies [4]. There is a large body of 
evidence on the associations between DNA repair and the 
risk of cancer, including CRC [5].
The repair of double-strand breaks (DSBs), the 
most deleterious type of DNA damage, is a fundamental 
cellular mechanism to preserve genomic stability [6]. Two 
pathways are specifically dedicated to the repair of DSBs: 
homologous recombination (HRe) and non-homologous 
end joining (NHEJ) [7–9]. The repression of these efficient 
repair systems permits an accumulation of damage in 
rapidly dividing cells (such as cancer cells) that can induce 
apoptosis. Such an effect may also be exerted by radiation 
therapy (an inducer of DSBs) in cancer patients [7, 9, 10].
DNA repair capacity varies markedly among 
individuals, and there is evidence that its decrease is 
associated with increased cancer risk [11, 12]. In this 
respect, DNA repair genes present numerous single 
nucleotide polymorphisms (SNPs) with different 
allelic distributions in the general population. Some of 
these SNPs have been reported to be associated with 
cancer susceptibility in a number of malignancies that 
include CRC [13]. We have previously investigated 
associations between functional SNPs in DNA repair 
genes (including DSB repair genes XRCC3 and NBS1) 
and CRC susceptibility in cases and controls from the 
Czech Republic [14, 15]. Our findings have suggested that 
variations in DNA repair genes may be associated with 
cancer susceptibility through an altered repair function 
that can also explain some of the phenotypic differences 
observed in CRC [11, 16, 17].
In recent years, there has been a growing interest 
in the role of post-transcriptional regulation of gene 
expression modulated by microRNAs (miRNAs). In 
concomitance, the importance of the SNPs located within 
miRNA-binding target sites (miRSNPs) on cancer risk has 
been highlighted [18, 19]. Regulation and coordination 
between genes involved in the DNA repair pathways are 
fundamental for maintaining genome stability, and post-
transcriptional gene regulation by miRNAs is one of the 
critical players in these processes [20]. Thus, subtle effects 
displayed by SNPs in DNA repair signaling genes may 
account for some of these variations. In this sense, specific 
polymorphisms in regulatory regions such as miRNA 
target sites may also modulate survival and response to 
therapy in cancer patients [18, 21]. 
We recently reported associations between miRSNPs 
in genes of 3 DNA repair pathways (Nucleotide Excision 
Repair, Base Excision Repair and Mismatch Repair) and 
CRC risk or clinical outcome [21–23]. SNPs in miRNA 
target regions of important genes for DSBs repair may 
also affect the efficiency of translation of corresponding 
proteins. Thus, in the present study, we hypothesized that 
variations in DSB genes may modulate signaling response 
and the maintenance of genomic stability ultimately 
affecting cancer susceptibility, cancer survival and 
efficacy of chemotherapy. We investigated the role of 21 
polymorphisms in miRNA predicted target sites of NHEJ 
and HRe genes in association with CRC risk and its clinical 
outcome in cases and controls from the Czech Republic.
RESULTS
miRSNP selection
Out of the 21 genes involved in the HRe pathway, 
only 11 had polymorphisms predicted to bind miRNAs in 
their 3′UTRs. After further selection based on MAF and 
LD study criteria (see Materials and Methods section), 
15 miRSNPs within the 3′UTRs of seven genes (RAD51, 
RAD52, BRCA1, MRE11A, NBN, GEN1 and XRCC2) were 
identified. For NHEJ, from the initial seven genes involved 
in the pathway, a total of 39 miRSNPs in the 3′UTRs were 
found. Since the majority of the SNPs are not represented 
in the Caucasian population, only six polymorphisms in 
four genes (XRCC4, XRCC5, LIG4, and NHEJ1) passing 
the selection criteria were finally included in the study.
Case-control study
The characteristics of the study participants are 
presented in Table 1 [21]. 
None of the 21 SNPs deviated from Hardy-Weinberg 
equilibrium in control subjects. The strongest association 
with CRC susceptibility was observed for rs2155209 in 
MRE11A, a gene involved in HRe. The variant genotype CC 
of this SNP was associated with a decreased risk of cancer 
(odds ratios (OR) 0.54, 95% confidence intervals (CI) 0.38–
0.76, p = 0.0004). This association remained significant also 
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after correction for multiple testing. Moreover, a similar 
significant association was observed when stratifying the 
case group according to tumor site (for rectal cancer: OR 
0.32, 95% CI 0.18–0.59, p = 0.0002; for colon cancer: 
OR 0.66, 95% CI 0.45–0.96, p = 0.03) (Table 2 and 
Supplementary Table 1). Conversely, the variant genotype 
AA of RAD52 rs1051669 was associated with increased risk 
of cancer (OR 1.68, 95% CI 1.11–2.54, p = 0.01).
After stratification for tumor site, two 
polymorphisms in RAD52 gene (rs1051669 and 
rs11571475) were associated with colon cancer risk while 
one SNP in NBN (rs14448) was associated with rectal 
cancer risk. In particular, carriers of the AA genotype or 
the variant A allele in rs1051669 were at increased risk to 
develop cancer in the colon (OR 1.78, 95% CI 1.13– 2.80, 
p = 0.01 and OR 1.72, 95% CI 1.10–2.692, p = 0.02, 
respectively); whereas carriers of the heterozygous TC 
genotype of rs11571475 were at decreased risk to develop 
colon cancer (OR 0.76, 95% CI 0.58–1.00, p = 0.05). This 
last observed association should be cautiously considered: 
in the dominant model the presence of the variant C allele 
was associated with a decreased risk of colon cancer 
(OR 0.74, 95% CI 0.57–0.97, p = 0.03). However, due to 
the low frequency of the CC genotype in our study group 
it was not possible to observe the same effect in the co-
dominant model (Table 2). A decreased risk of rectal cancer 
was observed for carriers of the heterozygous genotype in 
rs14448 (OR 0.41, 95% CI 0.21–0.80, p = 0.01). 
Globally, no significant associations with the risk of 
CRC were found for any of the studied polymorphisms 
in the NHEJ pathway. The only observed exception was 
for XRCC5 rs1051677 when comparing only rectal cancer 
patients with controls (codominant model: OR 3.84, 95% 
CI 1.11–13.31, p = 0.03; recessive model: OR 3.75, 95% 
CI1.08–12.95, p = 0.04) (Supplementary Table 2).
Contingency tables for SNP interaction analyses
As the variants under investigation are part of two 
DNA repair pathways where genes work functionally 
coupled, the polymorphisms emerging from the case-
control study were also explored for their potential 
SNP-SNP interaction in modulating CRC susceptibility. 
In general, the results revealed a tendency for the under-
representation of cases in comparison with controls 
among carriers of the variant rs2155209 genotype CC 
in MRE11A in combinations with other SNPs in genes 
of HRe pathway (Supplementary Table 3). Among the 
most interesting results, the observed protective effect of 
rs2155209 was increased by the concomitant presence 
of AA genotype of XRCC2 rs3218547, whose protective 
effect was not reaching the significance when analysed 
alone. Conversely, there was an under-representation of 
RAD52 rs1051669 AA genotype (alone associated with an 
increased risk to develop cancer) in carriers of the variant 
C allele of rs2155209 (Supplementary Table 3). 
Survival analyses
The mean (median) overall survival (OS) and event-
free survival (EFS) for patients were 86.5 (80.5) and 
72.6 (62.4) months, respectively. Age, gender, T, N, M 
status, chemotherapy treatment and CRC stage were 
associated with OS and EFS in the preliminary univariate 
assessment of covariates (Table 3). Advanced age, male 
gender and current smoking status were related to a shorter 
OS. Likewise, men were also at higher risk of relapse or 
metastasis (OS: Hazard ratio (HR) 1.54; 95% CI 1.23– 1.92; 
p = 0.0001; EFS: HR 1.35; 95% CI 1.09–1.68; p = 0.006). 
Four established prognostic factors (T, N, M status and 
stage) were associated with decreased patients’ survival 
and increased risk of recurrence. Moreover, adjuvant 
chemotherapy was also associated with survival (Table 3).
After adjusting for above significant covariates, CRC 
patients, particularly those with colon cancer carrying the 
TT genotype of RAD52 rs11226, displayed a longer survival 
in a recessive model (HR 0.70; 95% CI 0.52–0.93; p = 0.02 
and HR 0.60; 95% CI 0.41–0.89; p =  0.01, respectively; 
Supplementary Table 4). Overall, patients also showed a 
similar significant trend across genotypes in the Kaplan–
Meier curves (log-rank test p = 0.004; Median survival time 
(MST) for CT carriers was 136 months; MST not reached 
for the other genotypes; Figure 1). Likewise, a similar 
trend was also found for colon cancer patients (log-rank 
test p = 0.005; MST for CT carriers was 162 months; MST 
not reached for the other genotypes; data not shown). Colon 
cancer patients with the variant CC genotype of MRE11A 
rs2155209 showed a shorter survival when compared 
with the most frequent TT genotype (HR 1.63; 95% 
CI 1.06– 2.51; p = 0.03) or with T-allele carriers (HR 1.54; 
95% CI 1.03–2.31; p = 0.04) (Supplementary Table 4). 
A similar trend was observed in the univariate Cox model 
and in the relative Kaplan–Meier curves (log- rank test 
p  = 0.005; MST for CC carriers being 99 months; MST not 
reached for the other genotypes; Figure 2). No significant 
association with recurrence risk was observed for any of the 
HRe genes (Supplementary Table 5).
Overall, no strong associations with survival and risk 
of recurrence were observed for all analysed miRSNPs in 
NHEJ genes (Supplementary Table 6 and Supplementary 
Table 7). Among CRC cases, carriers of the GG genotype 
of XRCC5 rs1051685 showed a decreased survival (OS: 
HR 2.12; 95% CI 1.04–4.32; p = 0.04). A similar trend was 
observed in the univariate Kaplan–Meier curves, although 
not being statistically significant (log-rank test p = 0.07; 
MST for AA and AG carriers = 176 and 178 months, 
respectively; MST for GG carriers = 65 months).
Luciferase assay
The role of rs2155209 in modulating MRE11A 
expression was investigated by a dual 3′UTR luciferase 
reporter assay. A statistically significant difference 
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between the two constructs carrying the different alleles of 
the SNP was observed (p = 0.007, MANOVA). Figure  3 
shows the luciferase activity following transfection 
with the pmirGLO vector without the 3′UTR (used as 
reference and set as 100%) and with the vectors carrying 
the alternative alleles in HCT-116 cell line. The average 
luciferase activity of the vector carrying the C-allele 
showed a reduction by 14% in comparison with the values 
obtained for the construct with the T-allele.
Validation on TCGA database
RNA sequencing (RNAseq) data of CRC patients 
in The Cancer Genome Atlas (TCGA) database were 
downloaded. The results from RNAseq from 327 tumor 
tissues and 13 normal-appearing, adjacent mucosa 
were available [24]. A general overexpression of all 20 
transcripts of MRE11A was observed in the tumor tissues 
when compared with healthy tissues (for all p < 10−7).
DISCUSSION
In the present study, we investigated the role of 
21 miRSNPs in DSB repair genes in modulating CRC 
susceptibility and clinical outcome. The major finding was 
the association of the variant CC genotype of MRE11A 
rs2155209 with a decreased risk of CRC. This association 
was observed independently of the stratification of the 
cases according to tumor site recorded at diagnosis. The 
C-allele of the SNP was also related to a reduced activity 
of the reporter gene in a dual luciferase assay. 
MRE11A encodes for a protein that is a component 
of the MRE11-RAD50-NBS1 (MRN) complex involved in 
DSB repair by both HRe and NHEJ, in the maintenance of 
telomere integrity, in DNA recombination during meiosis, 
and in the signaling of DSB damage [25]. Mutations in 
NBS1, MRE11A, and RAD50 disrupting the functionality 
of MRN complex may lead to genome instability and 
carcinogenesis. For instance, these mutations have been 
Figure 1: Kaplan-Meier OS curves for RAD52 rs11226 in all CRC patients. MST = median survival time.
Figure 2: Kaplan-Meier OS curves for MRE11A rs2155209 in colon cancer patients. MST = median survival time. 
Oncotarget5www.impactjournals.com/oncotarget
Table 1: Characteristics of the study population
Cases Controls OR 95% CI P
Age (years) [18,47] 90 591 Ref
(47, 55] 208 422 3.24 2.45–4.27 < 0.00001
(55, 65] 375 286 8.61 6.57–11.28 < 0.00001
(65,91] 438 170 16.92 12.74–22.47 < 0.00001
Sex Females 433 660 Ref
Males 678 809 1.28 1.09–1.50 0.003
BMI [0, 23.7] 187 367 Ref
(23.7, 26.2] 195 362 1.06 0.82–1.35 0.70
(26.2, 28.9] 229 323 1.39 1.09–1.78 0.01
(28.9, 53.1] 224 329 1.34 1.05–1.71 0.02
Smoking Non smokers 541 815 Ref
Smokers 161 328 0.74 0.59–0.92 0.006
Ex-smokers 341 253 2.01 1.65–2.45 < 0.001
Family History 
CRC
No 736 1204 Ref
Yes 146 142 1.68 1.31–2.16 < 0.0001
Living Area Town 520 952 Ref
Town and 
country
128 171 1.37 1.06–1.76 0.02
Country 244 269 1.66 1.35–2.04 < 0.00001
Education Primary 271 224 Ref
Secondary 473 819 0.48 0.39–0.59 < 0.00001
University or 
higher
141 345 0.34 0.26–0.44 < 0.00001
Abbreviations: BMI: Body Mass Index OR, odds ratio, 95% CI, confidence interval
Figure 3: Data show mean values of luminescence activity, normalized to Renilla luciferase levels, (FLUC/RLUC) 
from four independent experiments. MRE11A expression show a statistical significant (p = 0.007) decrease of about 14% in presence 
of the rs2155209 C-variant, compared to the expression obtained with the T-variant.
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reported for acute lymphoblastic leukemia [26], head and 
neck [27], prostate, breast and colorectal [28] cancers. 
MRE11A has been identified as a possible candidate for 
breast cancer susceptibility by Bartkova and colleagues 
[29]. Interestingly, MRE11 overexpression, commonly 
observed among cancer patients, has been postulated as a 
mechanism responsible for increasing cancer risk [24]. To 
support this hypothesis, RNAseq data available in TCGA 
database also show an overexpression of all available 
MRE11A transcripts in CRC tumor tissues when compared 
with their healthy tissue counterparts. In this sense, we 
may hypothesize that a miRNA post-transcriptional 
regulation of MRE11A may be finely modulated by the 
presence of the identified miRSNP, with the CC genotype 
contributing to a reduced risk of developing CRC. The 
low-risk allele (C) is in fact associated with a lower 
expression of MRE11A most probably due to the C-allele 
stronger interactions with the putative binding miRNAs, as 
suggested by the results of the functional study. 
To correctly interpret these results, we should not 
exclude the possibility that the observed association may 
be due to the linkage disequilibrium (LD) structure of the 
investigated locus. Rs2155209 in the Caucasian population 
is in a LD block spanning over 125Kbp and containing 
31 SNPs. Among those SNPs, it is the only one in the 
3′UTR and is indicated as one of the variants in the block 
describing one of the most common haplotypes (with a 
frequency of approx 25.4% of haplotypes harbouring the 
Table 3: Clinical and anamnestic characteristics significantly affecting Overall Survival (OS) and 
Event Free Survival (EFS) of the CRC patients with complete follow up (Cox regression)
OS EFS
Na HR (95% CI) P HR (95% CI) P
Sex Females 427 Ref Ref
Males 656 1.54 (1.23–1.92) 0.0001 1.35 (1.09–1.68) 0.006
Age (years) 55 ≤ 293 Ref Ref
56–62 248 1.43 (1.05–1.95) 0.02 1.41 (1.06–1.87) 0.02
63–70 294 1.39 (1.04–1.88) 0.03 1.19 (0.90–1.58) 0.22
> 70 248 2.02 (1.50–2.72) < 0.0001 1.04 (0.76–1.42) 0.80
Smoking habit* No 533 Ref Ref
Yes 493 1.26 (1.02–1.56) 0.03 1.14 (0.93–1.41) 0.19
pT 1 50 Ref Ref
2 166 2.64 (0.94–7.40) 0.06 2.18 (0.85–5.55) 0.10
3 535 5.84 (2.17–15.71) 0.0005 5.58 (2.30–13.53) 0.0001
4 136 9.21 (3.36–25.26) < 0.0001 6.96 (2.80–17.27) < 0.0001
pN 0 498 Ref Ref
1 260 2.17 (1.69–2.79) < 0.0001 1.87 (1.46–2.41) < 0.0001
2 68 3.40 (2.35–4.91) < 0.0001 3.43 (2.45–4.81) < 0.0001
pM 0 725 Ref Ref
1 177 4.80 (3.83–6.02) < 0.0001 4.56 (3.68–5.65) < 0.0001
5FU-based chemotherapy Yes 411 Ref Ref
No 440 1.42 (1.13–1.790) 0.003 0.85 (0.68–1.06) 0.14
Histologic Grade 1 125 Ref Ref
2 464 1.84 (1.26–2.69) 0.002 1.42(1.00–2.02) 0.05
3-4 199 2.35 (1.57–3.53) < 0.0001 1.88 (1.29–2.76) 0.001
Stage 1 149 Ref Ref
2 293 2.14 (1.32–3.48) 0.002 2.47 (1.51–4.05) 0.0003
3 244 3.75 (2.33–6.03) < 0.0001 3.87 (2.38–6.31) < 0.0001
4 177 11.87 (7.44–18.95) < 0.0001 11.86 (7.42–18.98) < 0.0001
*Ex-smokers included in non-smokers
Abbreviations: HR, hazard ratio; 95% CI, confidence interval. Significant results in bold.
a Numbers may not add up to 100% of available subjects because of missing information
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C allele) by Haploview software (HG19). The MRE11A 
3`UTR hosts several binding sites for transcription factors 
(for instance SMC3, CTCF, RAD21). However, the 
region surrounding rs2155209, and including the seed of 
the miRNAs predicted to bind on the SNP of interest, is 
not a site for RNA-binding proteins (RBPs), supporting 
the hypothesis of a miRNA related post-transcriptional 
mechanism. Although evidence highlighted a potential 
miRNA-dependent regulation of the gene, MRE11A 
expression could not be affected solely by rs2155209; 
other SNPs could be causally linked to the risk of CRC by 
different mechanisms.
A significant role for genetic factors in CRC has 
been confirmed by genome-wide association studies 
(GWAS) and large-scale replication studies, which 
have identified so far 124 SNPs associated with this 
cancer (the GWAS catalog: https://www.ebi.ac.uk/gwas/
search?query = colorectal% 20cancer). However, the 
loci identified were estimated to account collectively for 
approximately 6% of the excess familial risk of CRC [30], 
suggesting that additional SNPs remain to be identified. 
The rs2155209 polymorphism has also been previously 
associated with an increased risk of myocardial infarction, 
breast and bladder cancer [31–33]. For the latter, the 
rare allele was found at an increased risk, but genotype 
distribution in controls was not found in HW equilibrium. 
To the best of our knowledge, no reports have documented 
any association with CRC risk. Interestingly, other genetic 
variants in MRE11 (not in linkage with rs2155209) have 
been associated with various cancers including breast, 
bladder and ovarium [28, 29, 34, 35].
In the last years, the interest on miRNAs has increased 
since they have been recognized as pivotal players in 
diverse biologic processes, including DNA repair and DNA 
damage response [36, 37]. An increasing body of evidence 
indicates the possibility to use miRNAs as diagnostic, 
prognostic and predictive clinical biomarkers [20]. In this 
context, the presence of SNPs within the 3′UTRs of target 
DNA repair genes could alter the binding with specific 
miRNAs, modulating gene expression and ultimately 
affecting, besides cancer susceptibility [18, 22, 38], also 
therapy outcomes [39] and survival [21]. As an example, 
an association between a miRNA binding site SNP within 
the DNA repair gene RAD51 with bladder cancer risk and 
radiotherapy outcomes has been reported [39]. 
miRNAs typically mediate fine regulation of gene 
expression, tuning rather than altering protein levels [37]. 
There is evidence that miRNAs can control DNA damage 
response by interacting with DNA repair genes. Most of 
the studies have been conducted on cancer cell lines, and 
it is not clear whether miRNAs mediate DNA repair in 
healthy cells [37]. Most recently it has been hypothesized 
that high expression levels of DNA repair proteins are 
detrimental to DSB repair as the stoichiometry of factors 
in specific pathways is important. miRNAs could then 
facilitate DNA repair by maintaining the optimal levels 
of repair proteins [37], and there could be a further 
modulation mediated by SNPs in miRNA seeds or in target 
regions. In the context of CRC and DNA repair, our group 
has provided the first evidence that variations in miRNA-
binding sites in Base Excision Repair genes 3′UTRs 
may modulate prognosis and therapy response [21]. In 
the present study, among CRC patients, and specifically 
those with colon cancer, carriers of the TT genotype of 
RAD52 rs11226 displayed a better survival while carriers 
of the MRE11A rs2155209 variant CC genotype showed a 
shorter survival. Notably, MRE11 protein deficiency has 
been recently observed to be associated with improved 
survival of stage III colon cancer patients, independently 
of treatment [40]. This study supports our finding where 
CC genotype of MRE11A rs2155209 is associated with 
shorter survival. We can theorize that the modulatory role 
by the observed SNP on the expression of MRE11 protein 
may also influence the prognosis of cancer. RAD52 is a 
key protein in the homologous recombination pathway. 
In humans, it is known to exist in an oligomeric form 
in order to bind single-stranded DNA (ssDNA), to 
promote ssDNA annealing, to interact with RPA, and 
under certain specialized conditions, to simulate Rad51-
mediated homologous DNA pairing [41]. There is an 
established interplay between MRE11A and RAD52 genes 
since the binding of MRN complex to a DSB permits a 
following recruitment of RAD52 to start the resolution 
of the damage [42]. Both genes have numerous predicted 
binding miRNAs in their 3′UTRs, although only very few 
of them have been validated so far. We have investigated 
miRNAs predicted to bind to RAD52 and MRE11A 
where the SNPs found in association lie (reported in 
Supplementary Table 8). From the available data (source 
http://www.genecards.org/), many of these miRNAs are 
expressed in colon tissue. Interestingly, among them, two 
miRNAs (miR-1296 and miR-296–5p) are predicted to 
bind both genes. These miRNAs have been described 
deregulated in cancer and other diseases and, in particular, 
miR-296–5p has frequently been associated with cancer 
prognosis [43, 44].
Protein expression levels of NBS1, MRE11, and 
RAD50 in malignant tissues have also been measured in 
previous studies. For instance, it was observed that a lower 
MRE11 expression in tumor cells in bladder and breast 
tissues was also associated with worse cancer-specific 
survival compared with high expression [45, 46], and the 
underlying control mechanism determining these lower 
expression levels was essentially post-transcriptional and 
regulated by miR-153 [47]. Additionally, RAD50 and 
NBS1 mRNA levels correlated with expression of all three 
proteins, implying that transcription of these two genes 
determines the amount of MRN complex formed. In this 
sense, MRE11 protein levels seem to adapt in line with 
the complex formation, with the following degradation 
of protein molecules that are not required for complex 
formation [47]. This strong interconnection may explain 
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the other observed associations, in particular for the 
variants related to patient clinical outcome.
To our knowledge, this is the first study 
comprehensively investigating the role of SNPs residing 
in miRNA target sites of DSB repair genes in association 
with CRC risk and clinical outcome. The study population 
included in the present work is genetically homogeneous 
(all Caucasian from the Czech Republic), and clinically 
well-defined (cases and controls recruited in the same 
centers with follow-up data collected by the same 
physicians), thus excluding any possible population 
stratifications and bias. In addition, the inclusion of 
‘colonoscopically negative’ individuals ensured disease-
free control individuals because a negative colonoscopy 
result is the best available proof of the CRC absence 
[48]. Since this group of individuals may not necessarily 
represent the general population, we also included healthy 
cancer-free individuals recruited among volunteers from 
blood centers.
We are aware of certain limitations of the present 
investigation. In the case-control study, controls differed 
from cases in age and gender distribution, as well as 
other parameters such as BMI. However, we attempted 
to control tentative age effect by matching cases and 
controls by age quartiles through bootstrap sampling, and 
no changes were observed in the ten different resamplings. 
The main and novel finding of the present study 
was that MRE11A rs2155209 resulted strongly associated 
with a decreased risk of CRC, taking into account also 
multiple comparisons (by considering a 5% Bonferroni-
corrected significance threshold). Moreover, the presence 
of one or the other allele of rs2155209 was associated with 
a different luciferase activity. The present results support 
the emerging idea of a “miRNA network“ that may 
contribute to CRC [49]. Other miRSNPs, both in the same 
gene and in other DSB repair genes, were also associated 
with clinical outcomes highlighting the importance 
of this repair pathway in survival, most probably as a 
consequence of an impaired DNA repair system. 
It is generally accepted that all DNA repair pathways 
act in an integrative and collaborative way. Numerous 
factors affect the decision to repair a DSB via NHEJ or 
HRe, and accumulating evidence suggests these major 
repair pathways both cooperate and compete with each 
other at DSB sites to facilitate efficient repair and promote 
genomic integrity [50, 51]. We have observed in particular 
that both MRE11A and RAD52 share miRNAs predicted to 
bind to regions where SNPs were associated with survival 
while a SNP interaction analyses revealed an under-
representation of certain genotypes among concomitant 
genotypes of SNPs in both genes in association with CRC 
risk. However, a larger population is necessary to test the 
interaction/cooperation of different genes/SNPs in various 
pathways. 
In conclusion, we identified plausible candidate 
miRSNPs potentially affecting miRNA binding in DSB 
repair genes that were related either to CRC susceptibility 
or to patients‘ survival. Further studies are needed to 
replicate our findings and assess these miRSNPs as 
predictive biomarkers in independent populations, to 
functionally characterize the significant genetic variants 
and to find the biologic mechanisms underlying the 
associations.
MATERIALS AND METHODS
Study population and data collection
Blood samples were collected from 1126 patients 
with histologically confirmed CRC attending between 
September 2003 and October 2010 several oncological 
departments in the Czech Republic (three in Prague, 
one in Benesov, Brno, Liberec, Ples, Pribram, Usti nad 
Labem, and Zlin). Two control groups, whose samples 
were collected at the same time of cases recruitment, 
were included in the study. The first group consisted of 
688 hospital-based individuals admitted to five of the 
above mentioned gastroenterological departments that 
had negative colonoscopy results for malignancy or 
idiopathic bowel diseases (Control Group 1). The reasons 
for undergoing the colonoscopy were: i) positive fecal 
occult blood test, ii) hemorrhoids, iii) abdominal pain 
of unknown origin, and iv) macroscopic bleeding. The 
second group of controls consisted of 781 healthy blood 
donor volunteers (Control Group 2) collected from a blood 
donor centre in Prague. All individuals were subjected to 
standard examinations to verify the health status for blood 
donation and were cancer-free at the time of the sampling. 
Among the CRC cases, 397 patients were diagnosed with 
a tumor in the colon, 334 in the sigmoideum and 377 with 
rectal cancer (3 cases were lacking the information about 
the site of the tumor; however, since they had complete 
survival data, they remained in the survival analysis). Out 
of the 1469 controls, 688 were cancer-free colonoscopy 
inspected controls (Control Group 1) and 781 were healthy 
blood donor volunteers (Control Group 2). Details of CRC 
cases and controls have been reported previously [21].
All subjects were informed and provided written 
consent to participate in the study and to approve the use 
of their biological samples for genetic analyses, according 
to the Helsinki declaration. The design of the study was 
approved by the local Ethics Committee. Study subjects 
provided information on their lifestyle habits, BMI, 
diabetes, and family/personal history of cancer, using 
a structured questionnaire to determine demographic 
characteristics and potential risk factors for CRC. 
Follow-up of patients 
Eight hundred sixty-six CRC cases were monitored with 
follow-ups until August 31st, 2011. A second group consisting 
of 232 CRC patients was recruited later on and followed up 
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until March 31st, 2013. For all subjects, clinical data at the 
time of diagnosis, including location of the tumor, UICC 
(International Union Against Cancer) tumor-node-metastasis 
(TNM) stage system, grade and adjuvant chemotherapy 
treatment were collected, along with information about distant 
metastasis, relapse and date of death [52].
Four hundred and eleven CRC cases received a 
5-FU-based adjuvant regimen as first-line postoperative 
therapy. The therapy consisted of either a Mayo regimen, 
delivered as a bolus infusion of 5-FU (425 mg/m2) and 
leucovorin (10 mg/m2) for five days every four weeks 
six times or a simplified De Gramont regimen which 
consisted of a 2 h intravenous (i.v.) infusion of leucovorin 
(200 mg/ m2), then a 5-FU i.v. bolus (400 mg/ m2) 
followed by a 46h 5-FU continuous i.v. infusion 
(2400–3000 mg/m2). Four hundred forty subjects did 
not receive any adjuvant chemotherapy after surgery. In 
this study, the outcome variables measured were 5-FU-
based chemotherapy, OS (time from diagnosis until 
death or censorship), and EFS (time of surgery or end of 
chemotherapy until date of relapse, death or censorship).
Selection of candidate genes and SNPs in miRNA 
target binding sites
From the complete list of DNA repair genes 
available online (http://sciencepark.mdanderson.org/labs/
wood/DNA_Repair_Genes.html March 2014 version), 
seven genes were retrieved in the NHEJ pathway and 21 
genes in the HRe pathway. 
The approach used to select the candidate miRSNPs 
was similar to that described in [21]. Briefly, for each 
gene, SNPs within target binding sites for miRNAs 
were identified by using the freely available software: 
MicroSNiper (http://cbdb.nimh.nih.gov/microsniper [53], 
MiRSNP (http://202.38.126.151/hmdd/mirsnp/search/ 
[54]), Mirnsnpscore (http://www.bigr.medisin.ntnu.no/
mirsnpscore/ [55]), and Polymirt (http://compbio.uthsc.edu/
miRSNP/ [56]). The 50 detected SNPs were then filtered 
for their minor allele frequency (MAF > 5%) in Caucasian 
populations in the SNP database to reach an appropriate 
representation of all genotypes in our set of cases and 
controls. The information was primarily derived from 
1000genomes project database, phase 1, CEU population; 
whenever this was not possible, other reference populations 
were considered (i.e. HAPMAP CEU population) (dbSNP; 
http://www.ncbi.nlm.nih.gov/SNP/). SNPs with the 
required MAF were further tested for the possibility to 
be in LD using HaploView (v. 4.2) with the data from 
HapMap v. 3, release R2 in the CEU population. 
SNP genotyping
Genomic DNA was isolated from peripheral blood 
lymphocytes using standard procedures. The DNA from 
cases and controls was randomly placed on plates where 
an equal number of samples could be run simultaneously. 
The selected SNPs were genotyped using the KASPTM 
genotyping assay, a competitive allele-specific PCR SNP 
genotyping system (LGC Genomics, Hoddesdon, Herts, 
UK). For quality control purposes, duplicate samples (5% of 
the total numbers of samples) were repeated for each SNP, 
no template controls were included in each plate (NTCs).
DNA cloning and in vitro assay
A Dual-Luciferase reporter assay was used to 
investigate whether the MRE11A rs2155209 alleles were 
associated with a differential gene expression. Initially, 
a 1031 bp fragment of the 3′UTR region of MRE11A 
containing the T-allele of the SNP was PCR-amplified. 
The PCR primers were specifically designed to allow the 
cloning reaction with ClonEZ enzyme. The bases at the 
primers 3′ ends were specific to the region to be amplified, 
whereas the 15 bases at the 5′ ends were homologous to 
either side of the XhoI restriction site within the multiple 
cloning sites of the pmirGLO vector (Promega, Madison, 
USA). Each primer was also designed to include a 
XhoI restriction site sequence (c^tcgag) between the 
two sequences. The complete sequences were: sense 
primer = AACGAGCTCGCTAGCCTCGAGGGGTG 
ATAAATCTCTCCAGCTAATTC; and anti-sense 
primer = CAGGTCGACTCTAGACTCGAGAGCCC 
ATTGAGATACTTTTTTACTCAG. The vector was 
linearized with XhoI (NEB Inc, Ipswich, USA) and the 
PCR product was cloned downstream from the firefly 
luciferase (Photinus pyralis) reporter gene, using the 
Clone EZ PCR Cloning Kit (Genscript, Piscataway, USA). 
Competent cells NZY5α (NZYTech, Lisbon, Portugal) 
were used for transformation after the cloning reaction, 
as suggested by manufacturers. To obtain a vector with 
an MRE11A 3′UTR bearing the C-allele of rs2155209, 
the construct underwent site-specific mutagenesis using 
the Quick Change Lightning Site Direct Mutagenesis 
kit (Agilent, Milano, Italy). The sequences of the 
mutagenic primers were: sense = attgttttctcctttctgggtaaca 
cgccctaacttctg; and anti-sense = cagaagttagggcgtgttacccaga 
aaggagaaaacaat. Following the digestion of the parental 
(methylated) supercoiled double-stranded DNA with 
Dpn  I, XL10-Gold ultra-competent cells (Agilent, Milano, 
Italy) were used for transformation. 
For the functional assay, HCT-116 cells were plated 
at a density of approximately 7 × 104 cells per well in 
24- well plates and incubated overnight at 5% CO2, 
37°C in a humidified incubator. Cells were transiently 
transfected at about 80% confluence using 3 µl of Polyfect 
transfection reagent (Qiagen, Milano, Italy) and 0.4 µg of 
the chimeric construct carrying the T or the C allele. 
The assays were carried out using the dual-
luciferase reporter assay kit (Promega, Milano, Italy). 
A pmirGLO vector without 3′UTR insert was used as a 
reference. PmirGLO vectors contain the luciferase gene 
from Renilla reniformis (hRluc-neo), acting as a control 
reporter to normalize transfection efficiency. Twenty- four 
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hours after transfection, cells were washed with a 
phosphate-buffered saline solution and lysed with 100 µl 
of Passive Lysis Buffer (PLB Promega, Milano, Italy) for 
an optimal stability of the firefly and Renilla luciferase 
reporter enzymes. The culture vessel was shaken for 
8 minutes at room temperature. The lysates were used 
for measuring the activity of firefly (FLUC) and Renilla 
(RLUC) luciferases. Three replicates of all experimental 
points were performed in each experiment. For each 
transfection, luminescence intensity was evaluated by 
a luminometer (Optima FluoStar, BMG, Ortenberg, 
Germany), and luciferase activities were averaged from 
four measurements. The luminescence intensities of 
firefly and Renilla luciferase of the non-transfected cells 
(background) were subtracted from the values obtained for 
the transfected cells with the pmiRGLO vector containing 
the 3′UTR. The luminescence of the Renilla luciferase was 
used as the control reporter to calculate the normalized 
firefly luciferase activity (FLUC/RLUC activity).
Statistical analyses
Pearson`s chi-square test (1 degree of freedom), 
with a type-I error threshold set at α = 0.05, was used to 
verify whether the genotypes were in Hardy-Weinberg 
equilibrium in controls. SNPs were excluded from 
further analyses if the call rate was < 95%, deviated 
from Hardy-Weinberg equilibrium in controls at p < 102, 
or if genotypes were discrepant in more than 2% of 
duplicate samples. The multivariate logistic regression 
(MLR) analysis was used to test the association between 
genotypes and risk of CRC. The covariates analysed in the 
multivariate model were: sex, age, smoking habit (non-
smokers vs. smokers and ex-smokers), BMI, familial 
history of CRC, education level (high, intermediate and 
low) and living area (country, suburbs, and town). The 
associations between SNPs and CRC risk were calculated 
by estimating the ORs and their 95% CI, adjusted for both 
continuous and discrete covariates. For all the genotypes, 
regression coefficients for additive models were estimated. 
For each SNP, we evaluated its association with cancer 
risk using two different genetic models—dominant, and 
recessive—to define the best fitting model with the most 
significant p-value. The Bonferroni-corrected significance 
threshold is 0.002 (for 21 SNPs and α = 0.05).
The model with the highest likelihood was 
additionally checked for the significance of possible 
interaction terms in the MLR analysis. Statistical analyses 
were performed using R (http://www.rproject.org).
OS in CRC patients was estimated using the date 
of death or the date of follow-up termination as the end 
point. For the EFS, in patients who did not have distant 
metastasis at the time of diagnosis, date of relapse, 
death or end of the study were used as the end point of 
follow- up. EFS was defined as the time from surgery/
end of therapy to the occurrence of distant metastasis, 
recurrence or death, whichever came first. The survival 
curves for OS and EFS were derived by the Kaplan–Meier 
method (R version 2.14–2, Survival package). The relative 
risk of death was estimated as HR using Cox regression (R 
version 2.14–2, Survival package). Multivariate survival 
analyses were adjusted for age, gender, smoking and stage.
For the in vitro assays, the ratios (FLUC/RLUC) of 
the measurements of luminescence, each subtracted of its 
respective background, were compared between genotypes 
using the multifactor analysis of variance with interactions 
(MANOVA), where “experiment” and “genotype” were 
entered as independent factors in the model. The statistical 
tests were 2-tailed and carried out using Statgraphics 
Centurion software (StatPoint Technologies, Warrenton, Va).
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